EyeGene Inc - Asset Resilience Ratio

Latest as of March 2026: 53.36%

EyeGene Inc (185490) has an Asset Resilience Ratio of 53.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩34.53 Billion

≈ $23.40 Million USD Cash + Short-term Investments

Total Assets

₩64.70 Billion

≈ $43.85 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how EyeGene Inc's Asset Resilience Ratio has changed over time. Check EyeGene Inc (185490) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down EyeGene Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EyeGene Inc market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩34.53 Billion	53.36%
Total Liquid Assets	₩34.53 Billion	53.36%

Asset Resilience Insights

Very High Liquidity: EyeGene Inc maintains exceptional liquid asset reserves at 53.36% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

EyeGene Inc Industry Peers by Asset Resilience Ratio

Compare EyeGene Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for EyeGene Inc (2014–2025)

The table below shows the annual Asset Resilience Ratio data for EyeGene Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	51.88%	₩35.30 Billion ≈ $23.92 Million	₩68.05 Billion ≈ $46.12 Million	+3.36pp
2024-12-31	48.52%	₩31.68 Billion ≈ $21.47 Million	₩65.31 Billion ≈ $44.26 Million	-20.07pp
2023-12-31	68.58%	₩53.56 Billion ≈ $36.30 Million	₩78.10 Billion ≈ $52.93 Million	-13.14pp
2022-12-31	81.72%	₩65.69 Billion ≈ $44.52 Million	₩80.38 Billion ≈ $54.47 Million	+1.19pp
2021-12-31	80.54%	₩84.56 Billion ≈ $57.30 Million	₩104.99 Billion ≈ $71.15 Million	+6.18pp
2020-12-31	74.36%	₩33.04 Billion ≈ $22.39 Million	₩44.43 Billion ≈ $30.11 Million	-4.20pp
2019-12-31	78.56%	₩37.17 Billion ≈ $25.19 Million	₩47.31 Billion ≈ $32.06 Million	-7.96pp
2018-12-31	86.52%	₩46.76 Billion ≈ $31.69 Million	₩54.04 Billion ≈ $36.62 Million	+10.89pp
2017-12-31	75.63%	₩22.90 Billion ≈ $15.52 Million	₩30.28 Billion ≈ $20.52 Million	+9.68pp
2016-12-31	65.95%	₩12.24 Billion ≈ $8.29 Million	₩18.56 Billion ≈ $12.58 Million	-5.66pp
2015-12-31	71.61%	₩17.42 Billion ≈ $11.81 Million	₩24.33 Billion ≈ $16.49 Million	+35.39pp
2014-12-31	36.23%	₩2.01 Billion ≈ $1.36 Million	₩5.54 Billion ≈ $3.76 Million	--

pp = percentage points

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$45.69 Million

₩67.43 Billion KRW

Market Cap Rank

#22186 Global

#1355 in Korea

Share Price

₩1560.00

Change (1 day)

+6.19%

52-Week Range

₩1193.00 - ₩3355.00

All Time High

₩50300.00